Closing of EMCM divestment represents a significant strategic milestone for aap

aap Implantate AG (XETRA: AAQ.DE) announces that is has completed closing (notarization) of the agreement under which a Private Equity Company will acquire 100% of the shares of European Medical Contract Manufacturing B.V. (EMCM). EMCM is a contract manufacturing company and develops and manufactures medicinal products in the field of Biomaterials, Pharmaceuticals and Tissue Engineering.

The purchase price is EUR 18 million and payable in cash in three installments until the end of April 2014; one third of the purchase price has been received already.

Marek Hahn, CFO, comments: "The closing of this divestment represents a significant milestone in the strategic and financial progress we are making. It will allow us to build a broad based platform that can address the fundamental challenges in trauma healthcare, enabling new standards for infection prevention and resorbable implants."

As a result of the transaction, aap plans to update its financial guidance for 2014 in its consolidated annual financial statements, which are currently scheduled for publication on March 31, 2014.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap 's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments

For further information, please contact:

distributed by